Tris Pharma's Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution

Tris Pharma's Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
First-to-market generic equivalent of ProCentra® for treatment of ADHD and narcolepsy now available in the U.S.
 
MONMOUTH JUNCTION, N.J., July 10, 2013 -- /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that its generic pharmaceuticals business has launched Dextroamphetamine Sulfate Oral Solution, the first-to-market generic equivalent of ProCentra®, which is indicated for the treatment of attention deficit disorder with hyperactivity (ADHD) and narcolepsy.   
 
"Dextroamphetamine Sulfate Oral Solution continues Tris' track record of bringing first-ever generics to the marketplace, as it's our fourth first-to-market generic product and the first of many to be launched through our new generic pharmaceuticals business," said Ketan Mehta, President and CEO of Tris Pharma.
 
"With 13 FDA-approved ANDA products and a robust pipeline of ANDA development projects, we look forward to launching many more difference-making specialty generics," said Janet Penner, President of Tris' generic pharmaceuticals business.
 
Manufactured at Tris' U.S. Food and Drug Administration (FDA)-inspected, state-of-the-art facility in Monmouth Junction, NJ, Dextroamphetamine Sulfate Oral Solution is now available in the U.S. through wholesalers and distributors, as well as directly to the trade. Dextroamphetamine Sulfate Oral Solution was approved by the FDA on May 29, 2013. It is distributed in accordance with FDA and U.S. Drug Enforcement Administration (DEA) regulations governing the handling of CII controlled substances.
 
About Tris Pharma Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A. For more information, please visit http://www.trispharma.com.
 
ProCentra is a registered trademark of Outlook Pharmaceuticals, Inc., which is not associated with Tris Pharma.

Suggested Articles

UnitedHealthcare will stop covering Descovy in PrEP in favor of Truvada, which is on track to see low-cost generic competition in September.

AstraZeneca has signed into the EU’s first finalized COVID-19 vaccine supply agreement.  

The U.K.'s two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses while expanding clinical trials.